of thyroid function than are data on the T3 uptake or total T4 alone (1).
Materials
The following materials are provided in each kit: Clinical Assays: '251-labeled T3 (1 mCi/liter, 1600 kCi/mol) in phosphate-buffered physiological saline (10 mmol/liter, pH 7.0), tubes coated with rabbit anti-T3 serum, barbital buffer (50 mmol/liter, pH 8.0), euthyroid reference serum, hypothyroid control serum, and hyperthyroid control serum.
Nuclear-Medical
Laboratories,
Inc.: '251-labeled T3 (0.02 mCi/liter) in barbital buffer (pH 8.6), silicate adsorbent tablets (10-25% silicate), and euthyroid reference serum. 
Methods
Clinical Assays: All reagents, samples, and controls were brought to room temperature. To each coated tube were added 25 tl of patient serum, standard, or control, and 1.0 ml of 
Nuclear-Medical Laboratories,
Inc.: To each test tube were added 100 d of patient serum, standard, or control and 2.0 ml of 1251-labeled T3. The tubes were shaken simultaneously and 1 silicate adsorbent tablet was added to each tube. At least 1 mm after the last tablet was added, the tubes were mixed si- Added to each test tube were 100 zl of patient serum, standard, or control and 1.0 ml of macroaggregated albumin buffer solution which contained imIlabeled T3. The tubes' contents were vortex-mixed and left at room temperature for at least 5 mm. Then the tubes were centrifuged for 10 mm at 2000 to 2500 X g. The fluid in each tube was aspirated and the radioactivity in the tubes was counted for 2 mm.
Samples of serum from 60 unselected patients included samples from several women receiving estrogens or taking birth-control pills. Seven euthyroid serum controls were run along with the patient samples.
Results and DiscussIon
The linear regression plots (Figures 1-3 ) demonstrate good correlation among the three tests. When the manufacturer's normal range of 30 to 40% uptake is used, 80.0% (48/60) of the Clinical Assays values agree with the patient's clinical evaluation. For NML (normal range: 35-45%) the clinical agreement was 81.7% (49/60) and for DCA (normal range: 25-36%) it was also81.7% (49/60). Table 1 lists the various situations in which the T3 uptake test did not correspond to the clinical picture.
We emphasize that the T3 uptake test alone is not an adequate indicator of thyroid function and the manufacturers involved in no way imply anything to the contrary. This clinical noncorrespondence may be due to a variety of causes. whose serum showed low values for T3 uptake were on estrogens or birth-control pills, which are known to suppress T3 uptake (2).
The interassay mean of a euthyroid pool was determined by assaying the pool six times for four consecutive days. The mean (±SD) obtained by Clinical Assays was 36.9 ± 1.8% (CV 4.8%). The means (±SD) obtained by NML and DCA were 41.8 ± 0.9% (CV 2.1%) and 29.9 ± 1.2% (CV 3.9%), respectively.
We conclude that the Clinical Assays T3 uptake test gives results that agree very well with the uptake tests with which it was compared. The test is simple to perform and the results are reproducible.
The Clinical Assays test involves a relatively long incubation period, but this is somewhat offset by the obviation of a centrifugation step.
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